|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EXOC1 |
Gene summary for EXOC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EXOC1 | Gene ID | 55763 |
| Gene name | exocyst complex component 1 | |
| Gene Alias | BM-102 | |
| Cytomap | 4q12 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | A0A024RDA9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55763 | EXOC1 | P127T-E | Human | Esophagus | ESCC | 7.12e-17 | 2.94e-01 | 0.0826 |
| 55763 | EXOC1 | P128T-E | Human | Esophagus | ESCC | 1.03e-11 | 4.99e-01 | 0.1241 |
| 55763 | EXOC1 | P130T-E | Human | Esophagus | ESCC | 7.97e-20 | 4.11e-01 | 0.1676 |
| 55763 | EXOC1 | C04 | Human | Oral cavity | OSCC | 6.98e-09 | 4.54e-01 | 0.2633 |
| 55763 | EXOC1 | C21 | Human | Oral cavity | OSCC | 6.35e-37 | 8.72e-01 | 0.2678 |
| 55763 | EXOC1 | C30 | Human | Oral cavity | OSCC | 3.20e-15 | 5.63e-01 | 0.3055 |
| 55763 | EXOC1 | C38 | Human | Oral cavity | OSCC | 2.74e-05 | 7.02e-01 | 0.172 |
| 55763 | EXOC1 | C43 | Human | Oral cavity | OSCC | 1.63e-15 | 3.74e-01 | 0.1704 |
| 55763 | EXOC1 | C46 | Human | Oral cavity | OSCC | 8.11e-23 | 5.87e-01 | 0.1673 |
| 55763 | EXOC1 | C51 | Human | Oral cavity | OSCC | 4.50e-06 | 3.76e-01 | 0.2674 |
| 55763 | EXOC1 | C57 | Human | Oral cavity | OSCC | 1.51e-09 | 3.25e-01 | 0.1679 |
| 55763 | EXOC1 | C06 | Human | Oral cavity | OSCC | 8.04e-08 | 7.50e-01 | 0.2699 |
| 55763 | EXOC1 | C08 | Human | Oral cavity | OSCC | 1.89e-15 | 3.31e-01 | 0.1919 |
| 55763 | EXOC1 | C09 | Human | Oral cavity | OSCC | 1.12e-03 | 1.34e-01 | 0.1431 |
| 55763 | EXOC1 | LN46 | Human | Oral cavity | OSCC | 2.27e-06 | 3.58e-01 | 0.1666 |
| 55763 | EXOC1 | EOLP-1 | Human | Oral cavity | EOLP | 2.52e-03 | 9.41e-02 | -0.0202 |
| 55763 | EXOC1 | SYSMH1 | Human | Oral cavity | OSCC | 2.16e-21 | 4.82e-01 | 0.1127 |
| 55763 | EXOC1 | SYSMH2 | Human | Oral cavity | OSCC | 8.63e-10 | 2.84e-01 | 0.2326 |
| 55763 | EXOC1 | SYSMH3 | Human | Oral cavity | OSCC | 4.87e-17 | 4.71e-01 | 0.2442 |
| 55763 | EXOC1 | SYSMH4 | Human | Oral cavity | OSCC | 3.91e-02 | 4.92e-02 | 0.1226 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
| GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:000689215 | Esophagus | ESCC | post-Golgi vesicle-mediated transport | 82/8552 | 104/18723 | 4.00e-12 | 1.55e-10 | 82 |
| GO:001624114 | Esophagus | ESCC | regulation of macroautophagy | 102/8552 | 141/18723 | 1.09e-10 | 3.27e-09 | 102 |
| GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:000689315 | Esophagus | ESCC | Golgi to plasma membrane transport | 48/8552 | 60/18723 | 5.11e-08 | 9.16e-07 | 48 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:005070810 | Esophagus | ESCC | regulation of protein secretion | 142/8552 | 268/18723 | 9.31e-03 | 3.24e-02 | 142 |
| GO:005071416 | Esophagus | ESCC | positive regulation of protein secretion | 76/8552 | 137/18723 | 1.32e-02 | 4.31e-02 | 76 |
| GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
| GO:001623610 | Oral cavity | OSCC | macroautophagy | 192/7305 | 291/18723 | 7.01e-21 | 1.14e-18 | 192 |
| GO:001050610 | Oral cavity | OSCC | regulation of autophagy | 198/7305 | 317/18723 | 1.63e-17 | 1.51e-15 | 198 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EXOC1 | SNV | Missense_Mutation | c.2056N>C | p.Glu686Gln | p.E686Q | Q9NV70 | protein_coding | deleterious(0.03) | probably_damaging(0.98) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| EXOC1 | SNV | Missense_Mutation | rs192310507 | c.56G>A | p.Arg19His | p.R19H | Q9NV70 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EXOC1 | SNV | Missense_Mutation | c.324G>T | p.Lys108Asn | p.K108N | Q9NV70 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EXOC1 | SNV | Missense_Mutation | novel | c.1391C>T | p.Ser464Leu | p.S464L | Q9NV70 | protein_coding | deleterious(0.02) | benign(0.106) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EXOC1 | SNV | Missense_Mutation | c.1156N>T | p.Leu386Phe | p.L386F | Q9NV70 | protein_coding | tolerated(0.09) | probably_damaging(0.954) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EXOC1 | SNV | Missense_Mutation | c.2147T>G | p.Val716Gly | p.V716G | Q9NV70 | protein_coding | tolerated(0.13) | possibly_damaging(0.544) | TCGA-AR-A0TT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| EXOC1 | SNV | Missense_Mutation | rs745429232 | c.371G>A | p.Arg124Gln | p.R124Q | Q9NV70 | protein_coding | tolerated(0.57) | benign(0.351) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EXOC1 | SNV | Missense_Mutation | c.1148N>C | p.Arg383Thr | p.R383T | Q9NV70 | protein_coding | deleterious(0.01) | possibly_damaging(0.869) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| EXOC1 | SNV | Missense_Mutation | c.2251G>A | p.Glu751Lys | p.E751K | Q9NV70 | protein_coding | tolerated(0.28) | benign(0.3) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| EXOC1 | SNV | Missense_Mutation | c.758C>T | p.Ser253Phe | p.S253F | Q9NV70 | protein_coding | deleterious(0.04) | probably_damaging(0.926) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |